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Effects of fasting on serial measurements of
hyperpolarized [1-13C]pyruvate metabolism in
tumors
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Imaging of the metabolism of hyperpolarized [1-13C]pyruvate has shown considerable promise in preclinical studies
in oncology, particularly for the assessment of early treatment response. The repeatability of measurements of 13C
label exchange between pyruvate and lactate was determined in a murine lymphoma model in fasted and non-
fasted animals. The fasted state showed lower intra-individual variability, although the [1-13C]lactate/[1-13C]pyruvate
signal ratio was significantly greater in fasted than in non-fasted mice, which may be explained by the higher tumor
lactate concentrations in fasted animals. These results indicate that the fasted state may be preferable for the mea-
surement of 13C label exchange between pyruvate and lactate, as it reduces the variability and therefore should make
it easier to detect the effects of therapy. © 2016 The Authors. NMR in Biomedicine published by JohnWiley & Sons Ltd.
Additional supporting information may be found in the online version of this article at the publisher’s web site.
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INTRODUCTION
The introduction of hyperpolarized 13C-labeled cell substrates
has created a renewed interest in the field of MRS by allowing
the real-time assessment of tissue metabolism in vivo (1).
[1-13C]Pyruvate ([1-13C]Pyr) is the most well-studied substrate,
having shown promise in preclinical studies in oncology, partic-
ularly as an imaging marker for the detection of early response
to therapy and as a possible marker for tumor grading and early
lesion detection (2–5). Pyr has also translated to the clinic, with a
study in prostate cancer (6). As the end product of glycolysis, Pyr
can be reduced reversibly by NADH to generate lactate (Lac), in a
reaction catalyzed by lactate dehydrogenase (LDH), or
transaminated by glutamate to form alanine, in a reaction cata-
lyzed by alanine aminotransferase (ALT). Irreversible decarboxyl-
ation of Pyr to carbon dioxide, in a reaction catalyzed by
mitochondrial pyruvate dehydrogenase (PDH), may also occur
and, in some tissues, is sufficiently fast to give observable label-
ing of carbon dioxide and bicarbonate with a hyperpolarized 13C
label (7). Data from hyperpolarized 13C MRSI measurements are
often presented as either signal ratios (8) or apparent exchange
rates when the metabolite signals are analyzed as a function of
time. Both measurements are affected by Pyr delivery to the tu-
mor, tumor cell uptake and subsequent enzyme-catalyzed ex-
change (2,9–12).
Despite extensive preclinical use of hyperpolarized [1-13C]Pyr,
with promising future clinical applications in oncology
(2,13,14), notably in the serial assessment of treatment response,
there is a lack of information regarding the repeatability of these
measurements. The determination of repeatability is important
for an understanding of whether the observed changes in kinet-
ics of hyperpolarized [1-13C]Pyr conversion to Lac reflect real
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effects of therapy or, rather, changes in physiology and/or
method variability.
18F-Fluorodeoxyglucose positron emission tomography (18F-
FDG-PET), similarly to hyperpolarized [1-13C]Pyr, also assesses
an aspect of glycolysis. Several studies have evaluated the re-
peatability of 18F-FDG-PET, as well as the main factors underlying
the observed variability. A major factor affecting 18F-FDG uptake
is high blood glucose levels (15), as a result of competition be-
tween glucose and 18F-FDG for transport into the cell and subse-
quent phosphorylation. Therefore, it is recommended that, for
18F-FDG-PET examinations, there is some control over blood glu-
cose levels, either by overnight fasting (16) or by the measure-
ment of blood glucose levels at the time of injection (17).
We have investigated here whether the variability and repeat-
ability of measurements with hyperpolarized [1-13C]Pyr are also
affected by fasting.
MATERIALS AND METHODS
Tumor implantation and animal preparation
Tumors were established by subcutaneous inoculation of a suspen-
sion of 5×106 EL4murine lymphoma cells (in a volume of 100μL) in
the left flank of 8–10-week-old C57/Blk6 female mice. Tumors were
allowed to grow for 10days (volume, ~2 cm3; maximum diameter,
1.5 cm), after which the mice were divided into two cohorts: fasted
and non-fasted. Fasted mice were deprived of food for 18h prior
to the first 13C spectroscopic examination. Experiments were
conducted in accordance with project and personal licenses issued
under the United Kingdom Animals (Scientific Procedures) Act,
1986. Protocols were approved by the Cancer Research UK,
Cambridge Institute Animal Welfare and Ethical Review Body.
MRI/MRS protocols
Tumor-bearing mice were anesthetized initially by inhalation of a
mixture of O2 (0.3 L/min) and air (0.9 L/min) containing 3%
isoflurane (Isoflo, Abbotts Laboratories Ltd, Maidenhead, UK)
and were maintained during the MRS experiment with 1–2%
isoflurane in O2 and air, which was delivered via a facemask.
Animals were taped into a cradle to minimize breathing-related
motion, and placed in a heated MR probe, which maintained
the core body temperature at ~37 °C (monitored by a rectal
probe). Respiratory rate and body temperature were monitored
during the experiment using a Biotrig physiological monitor
(Small Animal Instruments, Stony Brook, NY, USA). A cannula
was inserted into a tail vein and its patency was maintained
through the use of heparin diluted in sterile physiological saline
(100U/mL). A 20-mm-diameter curved surface coil (Rapid
Biomedical GmbH, Rimpar, Germany) was placed over the tumor.
The entire assembly was placed in a 13C/1H volume coil (Rapid
Biomedical GmbH) in a 7-T horizontal bore magnet (Agilent, Palo
Alto, CA, USA). The tumor was localized using transverse 1H
images acquired using a spin-echo pulse sequence (TR = 1.5 s;
TE = 10ms; field of view, 40mm×40mm; data matrix,
128 × 128; slice thickness, 2mm; 15 slices).
Table 1. Mean coefficient of variation of kP and the hyperpolarized [1-
13C]lactate/[1-13C]pyruvate signal ratio in fasted and non-
fasted tumor-bearing mice following repeated measurements
HP [1-13C]pyruvate n (mice)
CCC
Mean SD COV (%)(95% CI)
Fasted
kP 8 0.89 (0.60–0.97) 0.141 0.016 11.773*
Lac/Pyr 8 0.83 (0.44–0.95) 5.671 0.942 14.998
Non-fasted
kP 8 0.62 (0.03–0.89) 0.1 0.021 24.767
Lac/Pyr 8 0.47 (0.14–0.82) 3.563 0.934 29.499
Fasted n kP Lac/Pyr
1st measurement 11 0.137 ± 0.05 5.49 ± 2.23**
2nd measurement 10 0.138 ± 0.06 5.41 ± 3.04
Non-fasted n kP Lac/Pyr
1st measurement 17 0.108 ± 0.04 3.67 ± 1.7
2nd measurement 8 0.107 ± 0.03 3.89 ± 1.25
CCC, concordance correlation coefficient; CI, confidence interval; COV, coefficient of variation; HP, hyperpolarized; kP, apparent
exchange rate constant of conversion of pyruvate to lactate; Lac, lactate; Pyr, pyruvate; SD, standard deviation.
kP and [1-
13C]Lac/[1-13C]Pyr signal ratios were calculated from the time courses of 13C labeling in lactate and pyruvate in tumors in
fasted and non-fasted mice, acquired 4 h apart. The mean, SD, intra-individual COV and CCC were calculated from 16
measurements for both the fasted and non-fasted animals.
*p=0.01, significantly different from non-fasted animals
**p= 0.02, significantly different from non-fasted animals
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[1-13C]Pyr hyperpolarization
Pyr was hyperpolarized as described previously (1). Briefly,
[1-13C]pyruvic acid samples (44mg, 14mol/L; 91% 13C), contain-
ing 15mmol/L of trityl radical, tris(8-carboxy-2,2,6,6-tetra-
(hydroxyethyl)-benzo-(1–5)-bis-(1,3)-dithiole-4-yl)-methyl sodium
salt (OX063; GE Healthcare, Amersham, Buckinghamshire, UK)
and 1.5mmol/L gadolinium chelate (Dotarem), were polarized
using a microwave source at 93.982GHz and 100mW for 1 h in
a 3.35-T Hypersense (Oxford Instruments Molecular Biotools Ltd.,
Abingdon, Oxfordshire, UK) polarizer. The frozen sample was then
dissolved in a solution containing 40mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 94mM NaOH, 30mM
NaCl and 50mg/L ethylenediaminetetraacetic acid (EDTA) at
~180 °C and ~1MPa. Polarization levels ranged from 16% to
25%, measured using a bench-top polarimeter (13C-MQC polarim-
eter, Oxford Instruments Molecular Biotools Ltd., Abingdon,
Oxfordshire, UK).
NMR spectroscopy of tumors
From the total number of animals (n=30), paired data were only
obtained from 16 animals, as the remainder showed a poor
signal-to-noise ratio in the 13C spectra from one of the examina-
tions, reflecting the difficulty in obtaining good sequential tail
vein injections over such a relatively short period of time. Paired
13C spectroscopic data, acquired 4 h apart, were obtained from
eight fasted and eight non-fasted animals (Table 1). The mice
were examined on the same day as the tumor model showed
rapid growth (18,19), which could alter the metabolic status of
the tumor if the animals were examined on subsequent days. Af-
ter the first examination, mice were recovered from anesthesia
and food was provided only to the non-fasted group (Fig. 1).
Following intravenous injection of hyperpolarized [1-13C]Pyr
(10mL/kg, 82mM), single transient spectra from a 6-mm-thick
slice through the tumor were acquired using a slice-selective
excitation pulse with a nominal flip angle of 10°. One hundred
and twenty 13C spectra were acquired every 2 s beginning 10 s
after injection. The processing of 13C spectroscopic data was
performed in Matlab (Mathworks, Massachusetts, USA). The inte-
grated peak intensities of hyperpolarized [1-13C]Pyr and [1-13C]
Lac were fitted to the modified Bloch equation for two-site ex-
change to calculate the rate constants kL and kP and the appar-
ent spin–lattice relaxation rates, as described previously (2).
L
kP←
kL
→ P [1]
dLZ
dt
¼ R1;L LZ –L∞ð Þ þ kPPZ  kLLZ [2]
dPZ
dt
¼ R1;P PZ –P∞ð Þ þ kLLZ  kPPZ [3]
where LZ and PZ are the z magnetizations of the
13C nucleus in
the Lac and Pyr carboxyl carbons, respectively, R1,L and R1,P are
the spin–lattice relaxation rates (1/T1), and L∞ and P∞ are the
equilibrium magnetizations of Lac and Pyr, respectively, which
are effectively equivalent to their concentrations. The relaxa-
tion rates for Lac and Pyr were assumed to be the same. We
have shown previously that this assumption has little effect
on the fitted rate constants [see supplementary fig. 2 in ref.
(2)]. L∞/P∞ was obtained from the ratio of the fitted rate
constants. The 13C-labeled Lac/Pyr ratios were calculated from
LZ/PZ at 30 s.
Dynamic contrast-enhanced MRI (DCE-MRI)
Separate cohorts of mice, fasted (n= 7) and non-fasted (n=7),
were used for DCE-MRI measurements of tumor perfusion,
in which the mice were injected with Gd3+-DTPA (diethy-
lenetriaminepentaacetic acid; 200mmol/kg; Magnevist, Bayer
Schering Pharma, Leverkusen, Germany) (Table 2). The imaging
protocol simulated the protocol used for the 13C hyperpolarized
measurements. Briefly, for each cohort (seven fasted, seven non-
fasted), four mice were injected with contrast agent (1st scan) and
three mice were injected with unlabeled Pyr (82mM, 10mL/kg),
followed by injection of contrast agent 4h later (2nd scan) (Fig. 1).
Before each injection, animals were submitted to at least 30min of
anesthesia, which is the same time for which theywere anesthetized
for the hyperpolarized [1-13C]Pyr measurements.
DCE-MRI data were acquired using a T1-weighted spin-echo
pulse sequence, as described previously (12). Briefly, first an in-
version recovery fast low-angle shot (FLASH) pulse sequence
was used to measure the native spin–lattice relaxation rates
(R1 = 1/T1). These inversion recovery data were fitted, pixel-by-
pixel, to a mono-exponential function to obtain a pre-contrast
R1 map. A dynamic T1-weighted spin-echo pulse sequence was
then used to collect baseline images (6 or 10) prior to injection
of contrast agent. Diluted Gd3+-DTPA in sterile saline (0.9%
Figure 1. Schematic representation of study design. EL4 tumor-bearing
mice were randomly divided into two groups: fasted for 18 h and non-
fasted. Mice then underwent the same imaging protocol twice in the
same day, with a 4-h recovery period between examinations, in which
the non-fasted mice were given access to food. The first and second
13C spectroscopic examinations are referred to as the 1st and 2nd scans,
respectively. The tumor [1-13C]lactate/[1-13C]pyruvate ([1-13C]Lac/[1-13C]
Pyr) signal ratio, at 30 s after injection of hyperpolarized (HP) [1-13C]Pyr,
and kP were calculated from the time course of pyruvate (Pyr) and lactate
(Lac) labeling. In another group of animals, the ratio of the area under the
contrast agent concentration curve (AUC) in the tumor and adjacent
muscle was calculated after injection of contrast agent at each of the
two time points, with the mice at the second time point having had an
injection of unlabeled, non-HP, Pyr at the first time point. A different co-
hort of mice, prepared in the same manner, was sacrificed at three differ-
ent time points: baseline (BL, 0) (no injection of Pyr), 1 (after injection of
Pyr) and 2 (after two injections of Pyr, 4 h apart), with each mouse
submitted to at least 30min of anesthesia, which is the time for which
the animals were anesthetized for the HP [1-13C]Pyr studies.
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Figure 2. Repeatability of kP and [1-
13C]lactate/[1-13C]pyruvate ([1-13C]Lac/[1-13C]Pyr) signal ratio measurements in fasted mice (a–d) and non-fasted
mice (e–h) (see Fig. 1). Measurements in a single animal from the 1st scan (measurement 1) are plotted against measurements from the same animal
from the 2nd scan (measurement 2). The full line indicates the best-fit line between these two measurements (a & c, e & g). The broken lines indicate
the 95% confidence limits of the best-fit line. The dotted lines represent perfect agreement between the two measurements. For each mouse, the dif-
ferences in kP between the 1st and 2nd scans are plotted against the average of kP from the 1st and 2nd scans (b & f). This Bland–Altman (BA) plot (23)
was used to test the assumption of constant variances across the differences in kP. The full line at 0.00 is that of perfect agreement between the
measurements of kP from the 1st and 2nd scans, and the full line above is the mean difference of kP between the 1st and 2nd scans. The broken lines
indicate the 95% confidence limits of agreement. The dotted lines represent the 95% confidence intervals for these limits of agreement. The BA plots
for the [1-13C]Lac/[1-13C]Pyr ratios are shown in (d & h).
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sodium chloride) was then injected as a bolus through a tail vein
catheter over 2–3 s and dynamic T1-weighted spin-echo images
were acquired for 10min post-injection. These images were then
converted to R1 relaxation rate maps, as described previously
(12). Gd3+-DTPA concentration curves were determined for all
tumor-containing slices with a manually delineated region of
interest (ROI) in the tumor and also in adjacent thigh muscle.
The area under the uptake curve up to 45 s (AUC 45) was calcu-
lated for each ROI.
Blood and tissue collection and analysis
In a separate set of experiments (Table 3), tumor-bearing mice
(n= 24) were divided into two groups: fasted (n=12) and non-
fasted (n= 12). In each group, the mice were further divided into
three subgroups: Group 0, anesthetized for 30min; Group 1,
30min of anesthesia plus a bolus injection of 10mL/kg of
82mM unlabeled Pyr; Group 2, same as Group 1, plus a 4-h recov-
ery period, a second period of anesthesia for 30min and another
injection of 10mL/kg of 82mM unlabeled Pyr (Fig. 1). The timing
of anesthesia and Pyr injection was the same as for the 13C MRS
data acquisition protocol (Fig. 1). Blood was collected rapidly by
cardiac puncture in all mice from each group (starting at 25 s af-
ter Pyr injection) and the tumors were quickly excised and
freeze-clamped 30 s after Pyr injection.
Blood samples were centrifuged (18 800 g) at 4 °C for 5min in
heparin-coated Eppendorf tubes (~5 μL of 1000U/mL). Pyr was
analyzed using a colorimetric assay kit (AbCam, Cambridge,
UK) and Lac by an enzymatic assay kit (Siemens Healthcare,
Sudbury, UK), using a Siemens Dimension RxL analyzer.
Perchloric acid extracts were prepared from the tumor tissues
of Groups 1 and 2 for both fasted (n= 6) and non-fasted
(n= 6) mice using ice-cold 7% perchloric acid (1: 8w/v), which
were then neutralized with KOH, lyophilized and dissolved in
99.9% deuterium oxide. High-resolution 1H NMR spectra of
plasma and tumor extracts were obtained at 14.1 T (25 °C,
pH 7.2) in a Bruker 600-MHz NMR spectrometer (Bruker,
Ettlingen, Germany) using a 5-mm probe. The acquisition condi-
tions were as follows: 90° pulses; spectral width, 7.3 kHz; acqui-
sition time, 4.5 s; 32 k data points; 64 transients; recycling time,
12.5 s. Chemical shifts were referenced to 3-(trimethylsilyl)-
2,2′,3,3′-tetradeuteropropionic acid (TSP) at 0.0 ppm, which was
added to the sample at a concentration of 5mM. Data were an-
alyzed using ACDSpecManager (ACD/Labs, Bracknell, UK). The
free induction decays were zero-filled twice and multiplied by
an exponential function prior to Fourier transformation. Peak in-
tegrals were normalized to the integral of the TSP resonance.
Statistical analysis
Data were analyzed using SPSS (v21, IBM SPSS, Chicago, IL, USA)
and GraphPad Prism v6 (GraphPad Software, San Diego, USA).
The repeatability of measurements of kP and the [1-
13C]Lac/
[1-13C]Pyr signal ratio, which was measured at 30 s after
injection, were assessed from the two imaging examinations per-
formed 4 h apart. Scatter plots (Measurement 1 versus Measure-
ment 2) and Bland–Altman plots (difference versus mean) were
generated. The concordance correlation coefficient (CCC),
within-subject (intra-individual) standard deviation (SD) and
coefficient of variation (COV) were calculated as described in
refs. (20,21). The COVs of kP and the [1-
13C]Lac/[1-13C]Pyr signal
ratio were calculated, for each parameter, as the SD divided by
the parameter mean, and expressed as a percentage. This was
calculated for each individual and then averaged. COV can be
used as a statistical measure of reliability (22) and has been used
previously to assess reliability in FDG-PET studies (21). Data were
reported as mean± SD, unless stated otherwise. Statistical signif-
icance was tested with Prism using a two-tailed Student’s t-test
or analysis of variance (ANOVA) (post-hoc test: Tukey) when
appropriate. Paired t-tests were used when comparing paired
data from the same mouse. The results were considered to be
significant when p< 0.05.
RESULTS
Repeatability of 13C MRS measurements with hyperpolarized
[1-13C]Pyr
Intravenous injection of hyperpolarized [1-13C]Pyr (10mL/kg,
82mM) resulted in tumor signals from [1-13C]Pyr and [1-13C]Lac
that were similar in intensity to those observed previously in this
tumor model (2). The apparent rate constant describing the
conversion of Pyr to Lac (kP) and the [1-
13C]Lac/[1-13C]Pyr signal
ratios at 30 s were calculated. Previous studies in this tumor
model have shown that there is substantial labeling of both
the Pyr and Lac pools at 30 s after Pyr injection (2). The repeat-
ability of measurements made 4 h apart is shown in Fig. 2 and
Table 1. Non-fasted animals showed poorer correlations and
higher mean differences between successive measurements
than fasted animals. Repeatability was also assessed by calculat-
ing the COV for the mean kP and mean [1-
13C]Lac/[1-13C]Pyr
signal ratio using data from both time points, i.e. a total of 16
measurements for each group of animals (Table 1). Animals in
the fasted state showed lower intra-individual variability than
those in the non-fasted state, with significantly lower COV for
the mean kP (p=0.01). The higher metabolic rate of mice versus
Table 2. Measurements of tumor perfusion using dynamic contrast agent-enhanced 1H MRI
AUC (tumor/muscle)
Fasted 1st scan Fasted 2nd scan Non-fasted 1st scan Non-fasted 2nd scan
6.8 ± 2.8 9.7 ± 4.7 12.7 ± 5.6 5.9 ± 3.0
Tumor/muscle (thigh) ratio for the area under the contrast agent concentration curve (AUC) at 45 s after injection of contrast agent
for fasted and non-fasted EL4 tumor-bearing mice. Acquisitions were performed at the same time points as for the hyperpolarized
[1-13C]pyruvate study, with mice from Group 2 having received a dose of unlabeled non-polarized pyruvate (10mL/kg, 82mM) and
30min of anesthesia 4 h before the contrast agent-enhanced 1H images were acquired. Mean± standard error of the mean.
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humans means that 4 h is considered to be a substantial fasting
period for these animals and equivalent to an overnight fast in
humans. Moreover, in the 4-h period between the MRI examina-
tions, the mice were expected to feed multiple times (24).
The mean kP and [1-
13C]Lac/[1-13C]Pyr signal ratio calculated
from the first and second examinations showed no evidence of
a difference for both fasted (n=8) and non-fasted (n= 8) animals.
However, when using data from all the mice (n= 30), a higher
mean kP and [1-
13C]Lac/[1-13C]Pyr signal ratio were observed in
fasted mice than in non-fasted mice, with the difference in the
mean [1-13C]Lac/[1-13C]Pyr signal ratio observed between the
first measurements in the fasted (n=11) and non-fasted
(n=17) cohorts achieving statistical significance (p= 0.02)
(Table 1).
DCE-MRI
As both the [1-13C]Lac/[1-13C]Pyr signal ratio and kP may be
dependent on Pyr delivery (12), tumor perfusion was assessed
using DCE-MRI. There was considerable variation in contrast
enhancement between the different animals, as assessed from
the ratio of the area under the contrast agent uptake curves at
45 s for the tumor and adjacent muscle. There was no evidence
of perfusion changes between fasted and non-fasted mice at
the two time points (corresponding to the two measurements
with hyperpolarized [1-13C]Pyr) (Table 2).
Measurement of metabolite concentrations in tissue extracts
Tissue Lac concentration can affect 13C label exchange following
the injection of hyperpolarized [1-13C]Pyr and, consequently, the
[1-13C]Lac/[1-13C]Pyr signal ratio and kP (2,25). A significantly
lower tumor Lac concentration was observed in non-fasted than
in fasted mice after the first Pyr injection (Table 3). There was no
evidence of differences in tumor alanine concentrations (Table 3)
or in blood Lac levels between fasted and non-fasted mice
(Table 3). The blood Pyr concentration was significantly higher
in fasted mice after the first Pyr injection relative to non-fasted
animals (Table 3). There was no evidence of a difference
between the groups in terms of tumor weight; however, there
was a significant difference in animal weight between fasted
and non-fasted animals at baseline (Group 0) (Table 3).
DISCUSSION
The repeatability and variability of measurements with
hyperpolarized [1-13C]Pyr were determined in fasted and non-
fasted EL4 tumor-bearing mice. The initial values for the [1-13C]
Lac/[1-13C]Pyr signal ratio and kP were more similar to the values
measured 4 h later in fasted mice than in non-fasted animals
(Fig. 2), giving higher concordance coefficients in fasted animals
(Table 1). Both parameters showed higher COVs in non-fasted
mice (Table 1), where the unpredictable dietary intake before
and between examinations may have contributed to the higher
intra-individual variability in this group. The lower COV in fasted
mice (Table 1) is within a range similar to that seen with other
clinical imaging techniques, such as FDG-PET (26).
There was a significantly higher mean [1-13C]Lac/[1-13C]Pyr
signal ratio in fasted than non-fasted animals at the first time
point [5.49 ± 2.23 (n=11) versus 3.67 ± 1.70 (n=17), p= 0.02]
(Table 1) and a significantly higher tumor Lac concentration
[19.1 ± 2.7 versus 10.8 ± 4.1 (n= 3); p< 0.05] at this time point
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(Table 3). This is consistent with previous in vitro and in vivo stud-
ies (2,25,27), which have shown that the exchange rate increases
with an increase in Lac concentration. There was no evidence for
a difference in tumor perfusion between fasted and non-fasted
animals or between the first and second scans in these animals
(Table 2), although the error in these measurements was large.
Therefore, the higher tumor Lac levels in fasted mice implies that
these may have been caused by an increase in tumor glycolysis.
This has been observed previously in tumors of fasting animals,
where the tumor preferentially consumes glucose in comparison
with other tissues and produces increased amounts of Lac (28).
The fasted animals also showed higher blood Pyr levels after
the first injection of [1-13C]Pyr. This may be explained by
increased gluconeogenesis, which results in increased levels of
blood Pyr and alanine (29,30), and occurs independently of the
presence of a tumor (31,32).
The variability of hyperpolarized [1-13C]Pyr metabolism may de-
pend on the organ and/or type and grade of tumor being
assessed. Hyperpolarized [1-13C]Pyr was found to give reproduc-
ible results in the assessment of normal kidneys of non-fasted rats;
however, the fasted state was not examined in this study (33).
In conclusion, if hyperpolarized [1-13C]Pyr is to be used in the
clinic, especially for monitoring response to therapy or disease
progression using serial measurements, a knowledge of repeat-
ability is essential. The results presented here suggest that, sim-
ilar to what is already performed in some clinical centers for
18F-FDG-PET examinations (16,17,34), fasting prior to the MR ex-
amination might be preferred because of the more uniform and
constant metabolic status and lower intra-subject variability.
ACKNOWLEDGEMENTS
This work was supported by a Cancer Research UK Programme
grant (17242) awarded to K.M.B. and the Cancer Research UK &
Engineering and Physical Sciences Research Council (CRUK-
EPSRC) Imaging Centre in Cambridge and Manchester (16465).
E.M.S. is a recipient of a fellowship from the European Union Sev-
enth Framework Programme (FP7/2007-2013) under the Marie
Curie Initial Training Network METAFLUX (project number
264780). T.B.R. is a recipient of an Intra-European Marie Curie
(FP7-PEOPLE-2009-IEF, Imaging Lymphoma) fellowship and a
Long-term European Molecular Biology Organization (EMBO-
ALT-1145-2009) fellowship. E.M.S. acknowledges the educational
support of the Programme for Advanced Medical Education from
the Calouste Gulbenkian Foundation, Champalimaud Founda-
tion, Ministerio de Saude and Fundacao para a Ciencia e
Tecnologia, Portugal. The polarizer and related materials were
provided by GE Healthcare. The polarimeter was provided by
NIHR Cambridge Biomedical Centre. The laboratory is a member
of and receives support from the CRUK-EPSRC Cancer Imaging
Centre in Cambridge and Manchester.
This work was conducted under a research agreement with GE
Healthcare. K.M.B. and M.I.K. hold patents with GE Healthcare on
some aspects of the polarizer technology.
REFERENCES
1. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L,
Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-to-
noise ratio of >10,000 times in liquid-state NMR. Proc. Natl. Acad.
Sci. 2003; 100(18): 10 158–10 163.USA
2. Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J,
Golman K, Ardenkjaer-Larsen JH, Brindle KM. Detecting tumor
response to treatment using hyperpolarized 13C magnetic resonance
imaging and spectroscopy. Nat. Med. 2007; 13(11): 1382–1387.
3. Golman K, Zandt RI, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. Met-
abolic imaging by hyperpolarized 13C magnetic resonance imaging
for in vivo tumor diagnosis. Cancer Res. 2006; 66(22): 10 855–10 860.
4. Chen AP, Albers MJ, Cunningham CH, Kohler SJ, Yen YF, Hurd RE,
Tropp J, Bok R, Pauly JM, Nelson SJ, Kurhanewicz J, Vigneron DB.
Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse
at 3 T—initial experience. Magn. Reson. Med. 2007; 58(6): 1099–1106.
5. Serrao EM, Kettunen MI, Rodrigues TB, Dzien P, Wright AJ,
Gopinathan A, Gallagher FA, Lewis DY, Frese KK, Almeida J, Howat
WJ, Tuveson DA, Brindle KM. MRI with hyperpolarised [1-13C]pyru-
vate detects advanced pancreatic preneoplasia prior to invasive
disease in a mouse model. Gut 2015; 65(3): 465–475.
6. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL,
Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal
L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP,
Hurd RE, Odegardstuen LI, Robb FJ, Tropp J, Murray JA. Metabolic im-
aging of patients with prostate cancer using hyperpolarized [1-13C]
pyruvate. Sci. Transl. Med. 2013; 5(198): 198ra108.
7. Schroeder MA, Cochlin LE, Heather LC, Clarke K, Radda GK, Tyler DJ.
In vivo assessment of pyruvate dehydrogenase flux in the heart
using hyperpolarized carbon-13 magnetic resonance. Proc. Natl.
Acad. Sci. 2008; 105(33): 12 051–12 056.USA
8. Janich MA, Menzel MI, Wiesinger F, Weidl E, Khegai O, Ardenkjaer-
Larsen JH, Glaser SJ, Haase A, Schulte RF, Schwaiger M. Effects of
pyruvate dose on in vivo metabolism and quantification of
hyperpolarized 13C spectra. NMR Biomed. 2012; 25(1): 142–151.
9. Kettunen MI, Kennedy BW, Hu DE, Brindle KM. Spin echo measure-
ments of the extravasation and tumor cell uptake of hyperpolarized
[1-(13)C]lactate and [1-(13)C]pyruvate. Magn. Reson. Med. 2013; 70(5):
1200–1209.
10. Sogaard LV, Schilling F, Janich MA, Menzel MI, Ardenkjaer-Larsen JH.
In vivo measurement of apparent diffusion coefficients of
hyperpolarized 13C-labeled metabolites. NMR Biomed. 2014; 27(5):
561–569.
11. Bohndiek SE, Kettunen MI, Hu DE, Brindle KM. Hyperpolarized 13C
spectroscopy detects early changes in tumor vasculature and metab-
olism after VEGF neutralization. Cancer Res. 2012; 72(4): 854–864.
12. Bohndiek SE, Kettunen MI, Hu DE, Witney TH, Kennedy BW, Gallagher
FA, Brindle KM. Detection of tumor response to a vascular disrupting
agent by hyperpolarized 13C magnetic resonance spectroscopy. Mol.
Cancer Ther. 2010; 9(12): 3278–3288.
13. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY,
Kohler SJ, Tropp J, Hurd RE, Yen YF, Nelson SJ, Vigneron DB,
Kurhanewicz J. Hyperpolarized 13C lactate, pyruvate, and alanine:
noninvasive biomarkers for prostate cancer detection and grading.
Cancer Res. 2008; 68(20): 8607–8615.
14. Witney TH, Kettunen MI, Hu DE, Gallagher FA, Bohndiek SE,
Napolitano R, Brindle KM. Detecting treatment response in a model
of human breast adenocarcinoma using hyperpolarised [1-13C]pyru-
vate and [1,4-13C2]fumarate. Br. J. Cancer 2010; 103(9): 1400–1406.
15. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK,
Beauchamp RD, Shyr Y, Leach SD. Optimal interpretation of FDG
PET in the diagnosis, staging and management of pancreatic
carcinoma. J. Nucl. Med. 1999; 40(11): 1784–1791.
16. Surasi DS, Bhambhvani P, Baldwin JA, Almodovar SE, O’Malley JP.
18F-FDG PET and PET/CT patient preparation: a review of the litera-
ture. J. Nucl. Med. Technol. 2014; 42(1): 5–13.
17. Hamblen SM, Lowe VJ. Clinical 18F-FDG oncology patient prepara-
tion techniques. J. Nucl. Med. Technol. 2003; 31(1): 3–7 .quiz 8–10
18. Hu DE, Beauregard DA, Bearchell MC, Thomsen LL, Brindle KM. Early
detection of tumour immune-rejection using magnetic resonance
imaging. Br. J. Cancer 2003; 88(7): 1135–1142.
19. Hu DE, Dyke SO, Moore AM, Thomsen LL, Brindle KM. Tumor cell-
derived nitric oxide is involved in the immune-rejection of an immu-
nogenic murine lymphoma. Cancer Res. 2004; 64(1): 152–161.
20. Rockall AG, Avril N, Lam R, Iannone R, Mozley PD, Parkinson C,
Bergstrom D, Sala E, Sarker SJ, McNeish IA, Brenton JD. Repeatability
of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent
ovarian carcinoma: test–retest measurements for tumor FDG
uptake, diameter, and volume. Clin. Cancer Res. 2014; 20(10):
2751–2760.
21. Dandekar M, Tseng JR, Gambhir SS. Reproducibility of 18F-FDG
microPET studies in mouse tumor xenografts. J. Nucl. Med. 2007;
48(4): 602–607.
E. M. SERRAO ET AL.
wileyonlinelibrary.com/journal/nbm © 2016 The Authors. NMR in Biomedicine published by
John Wiley & Sons Ltd.
NMR Biomed. 2016; 29: 1048–1055
1054
22. Atkinson G, Nevill AM. Statistical methods for assessing measure-
ment error (reliability) in variables relevant to sports medicine.
Sports Med. 1998; 26(4): 217–238.
23. Bland JM, Altman DG. Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet 1986; 1
(8476): 307–310.
24. Jensen TL, Kiersgaard MK, Sorensen DB, Mikkelsen LF. Fasting of
mice: a review. Lab. Anim. 2013; 47(4): 225–240.
25. Hurd RE, Spielman D, Josan S, Yen YF, Pfefferbaum A, Mayer D. Ex-
change-linked dissolution agents in dissolution-DNP 13C metabolic
imaging. Magn. Reson. Med. 2013; 70(4): 936–942.
26. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST:
evolving considerations for PET response criteria in solid tumors.
J. Nucl. Med. 2009; 50(Suppl. 1): 122S–150S.
27. Witney TH, Kettunen MI, Brindle KM. Kinetic modeling of
hyperpolarized 13C label exchange between pyruvate and lactate
in tumor cells. J. Biol. Chem. 2011; 286(28): 24 572–24 580.
28. Goodstein ML, Richtsmeier WJ, Sauer LA. The effect of an acute fast
on human head and neck carcinoma xenograft. Growth effects on
an ‘isolated tumor vascular pedicle’ in the nude rat. Arch.
Otolaryngol. Head Neck Surg. 1993; 119(8): 897–902.
29. DiGirolamo M, Newby FD, Lovejoy J. Lactate production in adipose
tissue: a regulated function with extra-adipose implications. FASEB
J. 1992; 6(7): 2405–2412.
30. Exton JH, Corbin JG, Harper SC. Control of gluconeogenesis in liver.
V. Effects of fasting, diabetes, and glucagon on lactate and
endogenous metabolism in the perfused rat liver. J. Biol. Chem.
1972; 247(16): 4996–5003.
31. Norman TD, Smith AB. The blood lactic acid of tumor-bearing and
tumor-free mice. Cancer Res. 1956; 16(11): 1027–1030.
32. Rofe AM, Porter SJ, Bais R, Conyers RA. The metabolic response of
tumour-bearing mice to fasting. Br. J. Cancer 1985; 52(4): 619–623.
33. Zierhut ML, Yen YF, Chen AP, Bok R, Albers MJ, Zhang V, Tropp J, Park
I, Vigneron DB, Kurhanewicz J, Hurd RE, Nelson SJ. Kinetic modeling
of hyperpolarized 13C1-pyruvate metabolism in normal rats and
TRAMP mice. J. Magn. Reson. 2010; 202(1): 85–92.
34. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission
tomography: normal variations, pitfalls, and technical considerations.
Am. J. Roentgenol. 1997; 169(6): 1675–1680.
Supporting information
Additional supporting information can be found in the online
version of this article at the publisher’s website.
The raw data acquired during this study and on which the results
presented in this paper are based can be found at http://content.
cruk.cam.ac.uk/kblab/nbm3568.zip.
REPEATABILITY OF MEASUREMENTS WITH HYPERPOLARIZED [1-13C]PYRUVATE
NMR Biomed. 2016; 29: 1048–1055 © 2016 The Authors. NMR in Biomedicine published by
John Wiley & Sons Ltd.
wileyonlinelibrary.com/journal/nbm
1055
